Vasomedical set to maximise on expanded CHF (congestive heart failure) indication
This article was originally published in Clinica
Executive Summary
The market potential for Vasomedical's external counterpulsation (EECP) therapy was boosted this week by around seven-to-ten times, after the US FDA approved a new indication for the device - congestive heart failure (CHF).